Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Western blot [2]
- ELISA [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 500-P149-100UG - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- TNFRSF11B Polyclonal Antibody, PeproTech®
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Description
- AA Sequence of recombinant protein: METFPPKYLH YDEETSHQLL CDKCPPGTYL KQHCTAKWKT VCAPCPDHYY TDSWHTSDEC LYCSPVCKEL QYVKQECNRT HNRVCECKEG RYLEIEFCLK HRSCPPGFGV VQAGTPERNT VCKRCPDGFF SNETSSKAPC RKHTNCSVFG LLLTQKGNAT HDNICSGNSE STQK. Preparation: Produced from sera of rabbits immunized with highly pure Recombinant Human OPG. Anti-Human OPG-specific antibody was purified by affinity chromatography employing an immobilized Human OPG matrix. Sandwich ELISA: To detect Human OPG by sandwich ELISA (using 100 µL/well antibody solution) a concentration of 0.5-2.0 µg/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with PeproTech Biotinylated Anti-Human OPG (500-P149Bt) as a detection antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant Human OPG. Western Blot: To detect Human OPG by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 µg/mL. Used in conjunction with compatible secondary reagents the detection limit for Recombinant Human OPG is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.
- Reactivity
- Human
- Host
- Rabbit
- Vial size
- 100 µg
- Concentration
- 0.1-1.0 mg/mL
- Storage
- -20°C
Submitted references Bisphosphonates Reduce Smoking-Induced Osteoporotic-Like Alterations by Regulating RANKL/OPG in an Osteoblast and Osteoclast Co-Culture Model.
A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension.
Role of Wnt/β-catenin and RANKL/OPG in bone healing of diabetic Charcot arthropathy patients.
Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.
Zhu S, Häussling V, Aspera-Werz RH, Chen T, Braun B, Weng W, Histing T, Nussler AK
International journal of molecular sciences 2020 Dec 23;22(1)
International journal of molecular sciences 2020 Dec 23;22(1)
A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension.
Arnold ND, Pickworth JA, West LE, Dawson S, Carvalho JA, Casbolt H, Braithwaite AT, Iremonger J, Renshall L, Germaschewski V, McCourt M, Bland-Ward P, Kowash H, Hameed AG, Rothman AMK, Frid MG, Roger Thompson AA, Evans HR, Southwood M, Morrell NW, Crossman DC, Whyte MKB, Stenmark KR, Newman CM, Kiely DG, Francis SE, Lawrie A
Nature communications 2019 Nov 15;10(1):5183
Nature communications 2019 Nov 15;10(1):5183
Role of Wnt/β-catenin and RANKL/OPG in bone healing of diabetic Charcot arthropathy patients.
Folestad A, Ålund M, Asteberg S, Fowelin J, Aurell Y, Göthlin J, Cassuto J
Acta orthopaedica 2015;86(4):415-25
Acta orthopaedica 2015;86(4):415-25
Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.
Liu Y, Hawkins OE, Vilgelm AE, Pawlikowski JS, Ecsedy JA, Sosman JA, Kelley MC, Richmond A
Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Dec 1;21(23):5338-48
Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Dec 1;21(23):5338-48
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot: To detect Human OPG by Western Blot analysis TNFRSF11B Polyclonal Antibody (Product # 500-P149-1MG) can be used at a concentration of 0.1-0.2 µg/mL. Used in conjunction with compatible secondary reagents the detection limit for Recombinant Human OPG is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot: To detect Human OPG by Western Blot analysis TNFRSF11B Polyclonal Antibody (Product # 500-P149-1MG) can be used at a concentration of 0.1-0.2 µg/mL. Used in conjunction with compatible secondary reagents the detection limit for Recombinant Human OPG is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Sandwich ELISA: To detect Human OPG by sandwich ELISA (using 100 µL/well antibody solution) a concentration of 0.5-2.0 µg/mL of TNFRSF11B Polyclonal Antibody (Product # 500-P149-1MG) is required. This antigen affinity purified antibody, in conjunction with PeproTech TNFRSF11B Polyclonal Antibody, Biotin (Product # 500-P149BT-1MG) as a detection antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant Human OPG.
